{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Cai CX"],"funding":["NICHD NIH HHS","NEI","NEI NIH HHS","NCATS NIH HHS","NIA NIH HHS","NIDDK NIH HHS","NHLBI NIH HHS","NLM NIH HHS"],"pagination":["733-743"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298306"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(8)"],"pubmed_abstract":["<h4>Purpose</h4>To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab.<h4>Design</h4>Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network.<h4>Subjects</h4>Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion).<h4>Methods</h4>The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from eac"],"journal":["Ophthalmology. Retina"],"pubmed_title":["Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study."],"pmcid":["PMC11298306"],"funding_grant_id":["F30 HL168842","R01 AG068002","R01 LM006910","UL1 TR003098","U24 HD113136","R01 LM013426","K23 EY033440","K24 HL148181","K23 DK132459","K23 EY032985"],"pubmed_authors":["McLeggon JA","Matheny ME","Goetz K","Blacketer C","Suchard MA","Bu F","Desai P","Zhang L","Swerdel J","Lee E","Cai CX","Shoaibi A","Nagy P","Bowring MG","Lawrence-Archer L","Boland MV","Crews DC","Ng JH","Gilbert Z","Falconer T","Hall N","Ostropolets A","Tran D","DuVall SL","Nishimura A","Golozar A","Westlund E","Minty E","Cook M","Reps J","Toy B","Zeger SL","Sena AG","Jhaveri KD","Hripcsak G","Hribar M","Ryan PB"],"additional_accession":[]},"is_claimable":false,"name":"Similar Risk of Kidney Failure among Patients with Blinding Diseases Who Receive Ranibizumab, Aflibercept, and Bevacizumab: An Observational Health Data Sciences and Informatics Network Study.","description":"<h4>Purpose</h4>To characterize the incidence of kidney failure associated with intravitreal anti-VEGF exposure; and compare the risk of kidney failure in patients treated with ranibizumab, aflibercept, or bevacizumab.<h4>Design</h4>Retrospective cohort study across 12 databases in the Observational Health Data Sciences and Informatics (OHDSI) network.<h4>Subjects</h4>Subjects aged ≥ 18 years with ≥ 3 monthly intravitreal anti-VEGF medications for a blinding disease (diabetic retinopathy, diabetic macular edema, exudative age-related macular degeneration, or retinal vein occlusion).<h4>Methods</h4>The standardized incidence proportions and rates of kidney failure while on treatment with anti-VEGF were calculated. For each comparison (e.g., aflibercept versus ranibizumab), patients from eac","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-03-17T15:31:07.832Z","creation":"2025-08-16T03:06:58.908Z"},"accession":"S-EPMC11298306","cross_references":{"pubmed":["38519026"],"doi":["10.1016/j.oret.2024.03.014"]}}